Physician profile
Robert Raymond
NPI 1477550846
$2,916.97
in general payments reported to CMS, 2019-2025
17 companies · $604 in 2025
The $604 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.16 · 2021: $491 · 2022: $505 · 2023: $835 · 2024: $464 · 2025: $604.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,834 · Education: $69.67.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,833.61 |
| Education | $69.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $812.58 | 2020-2025 | |
| Janssen Biotech, INC. | $671.29 | 2021-2025 | Stelara, Tremfya, Remicade |
| Boston Scientific Corporation | $389.88 | 2022-2025 | Axios, Resolution 360 Ultra Clip, Autocap Rx |
| Gilead Sciences, INC. | $234.12 | 2021-2023 | |
| Celgene Corporation | $168.46 | 2021-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $150.12 | 2021-2024 | Entyvio, Gattex |
| Pfizer INC. | $72.96 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $72.41 | 2025 | Tremfya |
| Phathom Pharmaceuticals, INC. | $68.76 | 2024 | Voquezna |
| Nestle Healthcare Nutrition INC. | $49.77 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.47 | 2021-2024 | Trulance |
| Ferring Pharmaceuticals INC. | $47.01 | 2023 | Rebyota |
| Merck Sharp & Dohme LLC | $34.75 | 2021-2022 | |
| Celltrion USA INC. | $34.72 | 2023 | Yuflyma |
| Novartis Pharmaceuticals Corporation | $22.73 | 2024 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $19.36 | 2023 | Linzess |
| Intercept Pharmaceuticals, INC. | $18.58 | 2023 | Ocaliva |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Raymond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.